Julphar Releases Impressive Sales Figures

UAE generic drugmaker Julphar has revealed that its 2009 sales reached US$207mn, 21.9% higher than in 2008. The firm is confident it can continue on this upward trajectory and is expecting double-digit growth by the end of 2010. Even in light of such progress, Julphar has much to achieve to become a serious threat to Hikma, its main competitor already en route Middle East dominance.

To read the full article, please take a trial.